LGND:NASDAQ
Ligand Pharmaceuticals Inc
227,83 $
arrow_upward
+0,17%(+0,39) 1 p
4. mai, 15:59:35 GMT −4 · USD
search
Kõik sümbolid
1 p
5 p
1 kuu
6 kuud
YTD
1 a
5 a
MAX
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse LGND põhistatistika genereerimine…
Ava
226,47 $
Kõrge
233,98 $
Madal
226,20 $
Turu kapit.
4,57 mld
Keskm. maht
231,36 tuh
Maht
160,54 tuh
Hinna ja tulu suhe
37,15
52 näd kõrgeim
247,38 $
52 näd madalaim
98,89 $
Aktsiatulu
6,13 $
Beeta
1,12
Käibivad aktsiad
20,04 mln
Töötajate arv
47
Uudised
Erinevatest veebiallikatest
Stock Traders Daily
·
1 päeva eest
Price-Driven Insight from (LGND) for Rule-Based Strategy
Profiil
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Teave üksuse Ligand Pharmaceuticals Inc kohta
Tegevjuht-
Töötajad47
Asutatudsept 1987
PeakontoridJupiter, Florida, Ameerika Ühendriigid
Sektor-
Veebisaitligand.com
AI genereeritud sisu võib sisaldada vigu. Lisateave